LOS ANGELES, CA, November 19, 2022 /24-7PressRelease/ — The Everest Foundation was started in honor of the late Dr. Everest, a distinguished doctor, and educator. It operates under the leadership of Dr. Michael Everest and Agata Everest, who are committed to ensuring that the organization achieves its vision.
It funds innovative medical research initiatives critical to medical innovation and affordable healthcare. It invests in global initiatives such as higher learning and research grants.
The foundation also runs medical residency training programs. The foundation is committed to Graduate Medical Education. It partners with various medical schools to provide training opportunities to medical graduates.
It supports poor populations where people cannot access primary healthcare. In these countries, it is estimated that 2 million children succumb to an array of treatable diseases such as diarrhea and pneumonia.
The Everest Foundation is keen on alleviating suffering in vulnerable communities worldwide. More importantly, the foundation engages in venture philanthropy funding various charity initiatives in their areas and contributing to medical research.
It also places medical residents in underserved communities so that the population can get direct medical care.
Some medical specialties they study and support include internal medicine, Cardiology, Oncology, in-vitro fertilization, Gastrointestinal, Obstetrics, Pathology, Reproductive research, Gynecology, Opiates Addiction, Neurology, Psychiatry, and Infectious Diseases, among others.
It places a lot of emphasis on IDDM and Cardiac research. The Everest Foundation supports US medical research scholars, and some notable people have contributed significantly to medical research through the foundation’s help.
Agata Everest Supporting The Everest Foundation Scholars Dr. Patel, a medical scholar and a research fellow, has done outstanding research on Opioid use. Dr. Patel notes that it is essential to ensure proper stewardship when prescribing opioids.
She notes that a medical professional needs to prescribe the right opioids, the right dose of opioids, and for correct length. Incorrect prescriptions can negatively interfere with recovery and cause severe side effects.
The Everest Foundation funded Dr. Patel’s research initiative and provided her with the necessary medical equipment to carry out the research.
Dr. Ramalingam has also researched “clinicians-based paracentesis VS interventional radiology paracentesis.” Paracentesis is the perforation of a cyst or body part to diagnose an infection.
Medical scholars have divergent views on the more effective procedure for paracentesis between interventional and clinical-based radiology. Dr. Ramalingam took the trouble to research more about these two types of paracentesis.
It is ongoing research that uses an evidence-based approach and clinical tests. It will help the medical fraternity know the more effective type of paracentesis based on the clinical outcomes.
Agata Everest and the Everest Foundation are offering immense support to help her go about the research.
Another scholar that has been a beneficiary of the foundation is Dr. Obamiro. Dr. Obamiro has researched changing trends in orthopedic services due to the Covid 19 pandemic.
According to Dr. Obamiro, Covid 19 has changed how orthopedic care is given because of massive changes in the frequency of admissions and changing lifestyles. The research examines how the pandemic has affected planning, care, and preventive education.
Circumstances have compelled doctors and patients to change how they operate to keep human contact at a minimum.
To reduce the spread of Covid 19, some health facilities have introduced telehealth whereby patients can receive treatment from home using telemedicine technologies.
This is just one example of how orthopedic services have changed. Agata Everest and the Everest Foundation are glad to help Dr. Obamiro with her research, publication, and ultimately achieving a medical residency placement.
— Press release service and press release distribution provided by http://www.24-7pressrelease.com
Straits Research – Market Research Strategy | Strategy Consulting | Business Research | Business Consulting | Market Research
The global 3D printing medical devices market size was valued at USD 2.55 billion in 2022. It is projected to reach USD 9.79 billion by 2031, growing at a CAGR of 16.1{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} during the forecast period (2023-2031). North America is the most significant shareholder in the global 3D printing medical devices market.
New York, United States, Nov. 17, 2022 (GLOBE NEWSWIRE) — The process of producing three-dimensional solid objects from digital files or designs is referred to as additive manufacturing or 3D printing. Hollowing out or cutting a piece of metal or plastic makes it possible to produce intricate functional shapes. In 3D printing, an object is made by adding materials in successive layers until the desired shape is achieved. Throughout the healthcare lifecycle, medical printing devices provide users with a wide range of advantages. With the potential to be used as a widespread care pathway for complex injuries, 3D printing helps to improve treatment outcomes, procedural efficiency, and reintervention costs. During the forecast period, 2023–2031, medical and surgical facilities are anticipated to lead the demand for 3D-printed medical devices. The demand for 3D printed devices is also being boosted by the quick uptake of technological innovations such as portable, multi-material, colored 3D printers, and others in the medical sector. Additionally, 3D printing technology is revolutionizing the medical industry by enabling doctors to create individualized and patient-specific implants through novel applications in surgical implants and prosthetics.
The surge in 3D Printing Investment Drives the Market
The amount of public-private funding for various 3D printing initiatives has significantly increased in recent years. The market for 3D-printed medical devices is expected to grow as a result of these research and funding initiatives, which are expected to hasten the development of 3D printing technologies and products. In September 2020, the U.S. company nTopology raised $40 million in funding for the development of the nTop software platform for additive manufacturing methods. At the University of Huddersfield, a new generation of electron-beam additive manufacturing (EBAM) printer was developed with the help of USD 2.6 million in funding from Innovate U.K. in March 2019. (U.K.).
Digital Manufacturing Innovation gives Opportunity for Exponential Growth
With the aim of improving clinical workflow, there has been a significant advancement in the digitization of dental and medical procedures over time. Traditional dental and surgical procedures are being replaced by digital versions. Using computer-controlled processes, direct digital manufacturing is the process of making a physical object directly from a digital design. As 3D printing technology advances, direct digital manufacturing is becoming more and more popular in comparison to traditional manufacturing processes. Because it reduces the time between design and production, does away with the need for tooling, and increases output, it has a unique set of advantages.
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Component, Technology, Application
Geographies Covered
North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors
3D Systems Corporations, Bio3D Technologies, Cyfuse Medical K.K., EnvisionTEC, Materialise NV, Organovo Holdings, Inc., Oxford Performance Materials, Inc., SLM Solutions Group AG, and Stratasys Ltd.
Key Market Opportunities
The Surge of Digital Manufacturing
Key Market Drivers
Rising Investment in 3D Printing Increasing Cases of Osteoarthritis
North America is the most significant shareholder in the global 3D printing medical devices market and is expected to grow at a higher CAGR due to the region’s growing interest in 3D-printed medical devices and the rising demand for those devices. For instance, a U.S.-based service company called FORECAST 3D recently announced the purchase of 12 H.P. Jet Fusion 3D printers with the ability to provide full-run 3D manufacturing. In addition, the University of California (UCSF) and the Chinese 3D printer manufacturer INTAMSYS collaborated to launch the 3D printed orthopedics research initiative with technically advanced, reasonably priced orthopedic implants in June 2018.
Due to technological advancements, a strong and stable R&D environment, and innovation, Europe is expected to experience significant growth in the 3D printing medical devices market. Adidas and Carbon, a Silicon Valley 3D printing company, announced their collaboration in April 2017 to produce the “Futurecraft 4D” shoes, which feature 3D printed soles made using digital light synthesis technology. In July 2022, the 3D-printed bone graft manufactured by the medical device company Cerhum received approval for use in patients throughout Europe. MyBone is the first commercially available 3D-printed bone graft that has been authorized under the Medical Device Regulation 2017/745, according to reports. Additionally, it has obtained ISO 13485 certification. Thus, orthopedic and maxillofacial surgeons will now have access to the patient-specific bone graft across the continent.
During the anticipated period, the market for 3D-printed medical devices is likely to expand significantly in Asia Pacific. According to the E.U., as a result of government initiatives to promote the technological potential of orthopedics, the value chain for 3D-printed medical devices is gaining momentum. Additionally, nations like India and China are becoming more well-known due to factors like a rapidly aging population, a growing demand for cutting-edge healthcare, and others. In March 2022, Zoriox Innovation Labs will produce implants for facial reconstruction in India using 3D printing technology. In order to provide a 360-degree solution for facial reconstruction and related needs, a team of surgeons, dentists, mechanical engineers, biomedical engineers, software engineers, graphic designers, prosthetists, and anatomists collaborate at Zoriox Innovation Labs.
With several vendors expanding their operations and the implementation of favorable regulations in Latin America, the Middle East, and Africa, the LAMEA region is anticipated to experience moderate market growth. Using a 3D printed model of arteries to map out how to safely navigate the blood vessels, hospitals in Dubai have made it mandatory for doctors to use 3D printing to operate successfully on patients who have suffered a cerebral aneurysm in four veins.
Key Highlights
The global 3D printing medical devices market size was valued at USD 2.55 billion in 2022. It is projected to reach USD 9.79 billion by 2031, growing at a CAGR of 16.1{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} during the forecast period (2023-2031).
Based on components, the global 3D printing medical devices market is bifurcated into Printers, Materials, and Software & Services. The software and services segment is the highest contributor to the market.
Based on technology, the global 3D printing medical devices market is bifurcated into electron beam melting, laser beam melting, selective laser sintering, photopolymerization, direct metal laser sintering, and others. The laser beam melting segment is expected to grow at a higher CAGR during the forecast period
Based on application, the global 3D printing medical devices market is bifurcated into orthopedic & cranial implants, dental restorations, surgical instruments, tissue fabrication, and custom prosthetics.
North America is the most significant shareholder in the global 3D printing medical devices market and is expected to grow at a higher CAGR during the forecast period.
The global 3D Printing Medical Devices market’s major key players are
3D Bioprinting Market: Information by Technology (Magnetic Levitation) Application (Medical, Dental, Biosensors, Food, and Animal Products), and Region — Forecast till 2029
3D Printed Drug Market: Information By End User (Hospitals, Clinics, Research Laboratories) and Region— Forecast Till 2026
3D Optical Profiler Market: Information by Technology (Confocal Technology, White Light Interference), Industry Vertical, and Region — Forecast till 2026
3D Printing Materials Market: Information by Foam (Powder, Filament, Liquid), End-Use Industry (Automotive, Healthcare, Consumer Goods), Type, Technology, and Region — Forecast till 2029
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
This collaboration ensures first-of-their-kind consistent cannabinoid compositions for 575 DEA-licensed cannabis medical research institutions developing cures for PTSD, pain management, anxiety conditions and more
Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – November 16, 2022) – BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV), a leading biotech company focused on plant bio-cells growth for the nutraceutical and the medicinal cannabis markets, today announced the signing of a binding Letter of Intent (LOI) with Royal Emerald Pharmaceuticals (REP), one of only seven Drug Enforcement Administration (DEA) bulk manufacturing registration holders permitted to grow marijuana in the United States for drug related studies approved by the US Food and Drug Administration. This follows BioHarvest’s October 25th announcement that it could produce unique compositions based on a CBD hemp plant that dramatically increase cannabinoid concentrations (by weight) versus the original plant.
The 3-year initial term (with extension provisions) exclusive arrangement allows the supply of BioHarvest cannabis products for research purposes to pharmaceutical companies, research institutions and other DEA registered entities in the United States federally, and opens the door to advance cannabis research initiatives for drug development through cannabinoid compositions not found in nature. Under the multi-year deal, BioHarvest will be REP’s exclusive provider of cannabis that is produced from non-traditional cultivation methods for scientific, medical and research purposes across the DEA-regulated U.S. market. As part of the LOI, REP has participated with $1 million in BioHarvest’s convertible loan investment instrument that closed its second tranche on November 15th.
Cannabis-based medicines could be a boon to pharmaceutical companies that are threatened today by the legalization of cannabis. A number of studies have demonstrated a reduction in prescription drug use in Medicaid and Medicare populations directly resulting from the legalization of cannabis. Together, REP and BHSC can offer pharmaceutical companies consistent medical-grade cannabis at highly attractive manufacturing costs with signature patentable compositions tailored for addressing specific medical indications.
“I have unprecedented confidence in BioHarvest’s platform technology and their unique cannabis compositions especially after visiting their R&D and manufacturing facilities in Israel,” said Douglas Rosenberg, Chief Executive Officer of Royal Emerald Pharmaceuticals. “Cannabis-derived drugs are at the precipice of a tremendous opportunity right now as traditional pharmaceutical markets transition in search of innovation and technological advancements that are utilizing cannabis to deliver better solutions. Together we are well-positioned for the expected significant increase in U.S. demand for medical-grade cannabis for therapeutic research. I look forward to a productive and mutually prosperous partnership.”
“We’re extremely proud to partner with Royal Emerald to pair our breakthrough technology with their mission to revolutionize the cannabis medical research ecosystem by introducing unique and patentable cannabis compositions that are non-addictive and effectively treat a myriad of issues currently ailing our global communities,” said BioHarvest CEO Ilan Sobel. ” BioHarvest and REP are committed to developing life-changing solutions for major medical conditions which today are not being adequately treated by existing, chemically synthesized drugs. Imagine what can be accomplished if researchers and the medical community at large are assured of batch-to-batch consistency and the ability to fine-tune the Cannabis based therapy to specific medical indications. That is truly revolutionary.”
Using a patented technology in which vital plant cells are grown in bioreactors, BioHarvest has the unique ability to produce medicinal grade cannabis with consistent compositions by increasing, controlling, and fine-tuning the concentrations of different major and minor cannabinoids. This could help researchers to potentially develop previously unattainable cures for major health challenges such as ADHD, pain management, sleep disorders, and anxiety.
Dr. Christopher D’Adamo, Director of the University of Maryland School of Medicine’s Center for Integrated Medicine, described BioHarvest’s technology as a major advancement.
“Today marks a historical milestone in the pioneering and development of future full-spectrum cannabis drugs which the medical establishment has been eyeing its potential to address many chronic health indications in need of better treatment options,” D’Adamo said. “In addition, BioHarvest’s ability to provide signature cannabis compositions with a breadth of cannabinoids, and with batch consistency and patentability, will no doubt be a major incentive for companies to actively engage and invest in Cannabis based drugs”.
REP is one of only seven companies in the U.S. that hold DEA bulk-manufacturing licenses for scientific medical research. It is permitted to provide cannabis to at least 575 institutions that have DEA research licenses for cannabis research. They range from pharmaceutical companies to academic and medical institutions to government agencies such as the Department for Veterans Affairs and the National Institute on Drug Abuse. REP also has a General Services Administration license which enables the company together with BioHarvest to apply for major government grants from government agencies for cannabis research.
Under the LOI, and subject to the obtainment of the Israeli health authorities manufacturing license, the cannabis products supplied by BioHarvest will be produced in the facility in Israel. The future establishment of a manufacturing facility at REP’s premises in California is contemplated under certain conditions. The LOI also includes provisions with respect to future potential development of medical drugs by BioHarvest, REP and jointly.
Investor Webinar – Wednesday November 16, 2pm EST | 11am PST
Given the magnitude of this announcement, and what it means for the pioneering of cannabis drug development to focus on major indications that today are not being adequately addressed by pharmaceutical drug companies, the Company will host a special investor event today at 11am PST | 2pm EST, where BioHarvest Sciences CEO Ilan Sobel will be joined by the CEO of Royal Emerald Pharmaceuticals, Douglas Rosenberg. All interested media and investors are invited to preregister via this link: https://us02web.zoom.us/webinar/register/WN_y44ONRvVQ9Ou5bhWtHrvAA
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing biotech firm that has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.
About Royal Emerald Pharmaceuticals
Royal Emerald Pharmaceuticals is a California-based United States DEA and FDA-registered manufacturer and supplier of non-addictive cannabis products being developed for medical, scientific and research purposes. The company was founded on a shared mission to help veterans, first responders and others service personnel on the front lines that sacrifice for the greater good and as a result suffer from trauma-related issues such as PTSD and other health consequences. Royal Emerald is dedicated to serving our heroes by developing best-in-class cannabis derived pharmaceuticals to address their specific health and medical needs. Visit: https://www.royalemeraldrx.com/.
Contact:
BioHarvest Sciences Inc. Ilan Sobel, Chief Executive Officer
For further information, please contact: Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186 Email: info@bioharvest.com
Royal Emerald Pharmaceuticals Douglas Rosenberg, Chief Executive Officer
For further information, please contact: Jackie Devereaux, Director of Communications & Media Relations Phone 1 (760) 671-6944 Email: jdevereaux@royalemeraldrx.com
Forward Looking Statements
Information set forth in this news release includes forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Projected sales of Cannabis products will require the Company to obtain production and/or export licensing which cannot be assured. There is no assurance that the Company’s products will help researchers working on medications for heath challenges such as ADHD, sleep disorders. pain management and anxiety. Marketing products with such claims would require FDA approval in the US and similar approvals in other jurisdictions which would require a lengthy and expensive approval process including clinical trials the outcome of which would be uncertain and cannot be assured. Although the Company believes that the consistency and customizability of its products will make them more suitable for medical and scientific research there is no assurance that the customers of Royal Emerald or other medical/scientific users of cannabis products will choose the Company’s products over traditionally grown Cannabis Products. Adoption of new and disruptive products can be subject to structural obstacles and the uncertainty of market acceptance which may delay or even prevent adoption. There is no assurance that the Company and /or Royal Emerald will develop medical drugs which normally involves lengthy and expensive research and approval processes which may be beyond the ability of these parties and significant uncertainty of success.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
Setting up the unified procedure is intended to spur investigate programs with high opportunity to translate into client therapies and interventions, by strengthening connections amongst the primary sciences and clinical analysis. Undertaking so will speed up the procedure of making use of discoveries that enrich the detection and cure of ailment, mentioned Dr. Mukesh K. Jain, dean of drugs and biological sciences at Brown.
“Both Lifespan and Treatment New England have impactful research portfolios with good talent,” Jain said. “Bringing them alongside one another with Brown will make it possible for us all to expand on our existing assets in methods that benefit sufferers in our community and beyond. The vision getting state-of-the-art in this settlement integrates analysis from laboratory to medical trials to results at the inhabitants level throughout critical biomedical domains. I am unaware of any establishment regionally or nationally that aligns investigative endeavours throughout the entirety of the research continuum.”
Forming a Joint Govt Council
The ARC agreement was designed jointly in recent months and signed in early November. It outlines the formation of a 4-member Joint Executive Council that will give oversight on the organizations’ do the job to unify research operations. The functions agreed to a phased solution to employing important aspects of the ARC — the settlement marks the first phase and will start conversations on how to entirely operationalize the energy, with the Joint Government Council eventually needing to approve separate money and operational programs before ultimate implementation, predicted over the future 12 to 18 months.
“This settlement is an preliminary, but extremely essential, phase in aligning study throughout Brown, Lifespan and Care New England,” mentioned Dr. James E. Fanale, CEO and president of Care New England. “We are assured that from listed here, we can move ahead with operationalizing the approach and putting it into observe.”
The ARC’s operational program will go over matters together with research integrity and compliance, institutional evaluation boards and use of exploration services. It will also define information about study infrastructure, this sort of as staffing for the many positions expected to run investigation businesses effectively.
The gains of investigation alignment are major, together with for sufferers and people throughout the region, leaders from the corporations say.
“By fortifying and streamlining our investigation endeavours, I feel we will also be far more competitive in recruiting and retaining the best and brightest college, team and trainees in biomedical and health sciences,” stated Arthur Sampson, interim CEO and president of Lifespan.
Ronald Aubert, interim dean of the Brown University School of General public Overall health, stated that streamlining processes concerned in analysis administration will be 1 of the advantageous outcomes of this collaboration — the efficiencies enabled will direct to exploration efficiency that can in the long run profit people and populations.
“Having different administrative structures slows down the analysis procedure,” Aubert claimed. “Currently, if a Brown-based mostly researcher needs to collaborate with a medical center-based college member to full the objectives of grant-funded exploration, they have to perform within just the normally duplicative procedures of just about every process. What we hope to execute as we work by means of the operations piece of this collaboration is to empower our experts, community health and fitness gurus and medical professionals to do their investigate, not far more paperwork.”
Even though the settlement is not a merger topic to federal or condition merger laws, the businesses are jointly fully commited to compliance with the stringent federal rules governing investigation by which every separately abides now.
The agreement arrives just after Brown not too long ago released its last Operational System for Investing in Analysis, which offers a roadmap for growing scholarship with the aim of strengthening the good effect that Brown exploration has throughout the globe. The University is also investing in new money tasks to broaden exploration potential. Setting up is underway for a new integrated everyday living sciences building Brown intends to serve as anchor tenant in a community-private lifetime sciences development and the College signed a new lease for soaked lab space at Wexford Science & Technology’s Point 225 building. Each individual of these assignments is found in Providence’s Jewelry District in shut proximity to the Warren Alpert Professional medical Faculty and Treatment New England and Lifespan hospitals.
HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-countrywide epigenetics company, has announced a medical investigate examine with Oncovet, a renowned veterinary referral clinic, specializing in health care and radiation oncology.
The non-interventional research is remaining led by Dr. Jérôme Benoit, Oncovet’s Scientific Director, and will assess circulating nucleosomes of puppies and cats with cancer using Volition’s Nu.Q® Vet Most cancers Exam.
Volition’s Nu.Q® Vet Cancer Examination is a uncomplicated, uncomplicated-to-use blood take a look at currently out there for most cancers screening in canines with ongoing investigate into its use for cancer screening in cats, and ailment checking in both equally species.
Dr. Jérôme Benoit, Clinical Director at Oncovet, claimed: “Volition’s Nu.Q® Vet Cancer Examination has presently been proven to detect systemic cancers in pet dogs this sort of as lymphoma and hemangiosarcoma. We will seek to establish irrespective of whether other typical cancers that we on a regular basis see in clinic, could also be detected in pet dogs and cats by measuring circulating nucleosomes at prognosis and in the course of procedure.
“We are enthusiastic to function with the group at Volition, giving samples from 100 canine and 25 cats with a vast assortment of cancers, about the coming year. We glimpse forward to supporting Volition as the corporation expands its functions into Europe, enabling veterinarians and pet proprietors throughout the location to benefit from the Nu.Q® Vet Cancer Take a look at.”
Dr. Tom Butera, Main Government Officer of Volition Veterinary Diagnostics Growth LLC, said: “We are delighted to collaborate with Dr. Benoit and his group on this analysis research. Jérôme is very highly regarded within the veterinary oncology sector and Oncovet is very well recognized in Europe for the style and design and management of veterinary medical trials in pet dogs and cats.”
“We are hoping that this first study will be the get started of an successful, extensive-time period marriage with Oncovet, as we search for to broaden the vary of cancers that our Nu.Q® Vet Cancer Test can detect throughout diverse species. We glance ahead to sharing the final results.”
Volition is building very simple, effortless-to-use, cost-helpful blood checks to help diagnose and keep an eye on a range of lifetime-altering illnesses which includes most cancers in each individuals and animals. For extra data about Volition’s Nu.Q® technological innovation go to: www.volition.com.
Observe to editors:
Conclusions from a clinical research carried out by Volition and Professor Wilson-Robles and the staff at Texas A&M University, peer-reviewed and posted in August 2022, confirmed that:
About Volition
Volition is a multi-countrywide epigenetics company that applies its Nucleosomics™ system by way of its subsidiaries to build straightforward, quick to use, value successful blood exams to aid diagnose and watch a array of everyday living-altering health conditions including some cancers and illnesses connected with NETosis this kind of as sepsis and COVID-19. Early prognosis and monitoring have the opportunity not only to lengthen the life of patients but also to increase their quality of daily life. The exams are primarily based on the science of Nucleosomics™, which is the follow of pinpointing and measuring nucleosomes in the bloodstream or other bodily fluid – an sign that disease is existing.
Volition’s research and progress pursuits are centered in Belgium, with an innovation laboratory and business office in the U.S. and further places of work in London and Singapore.
The contents uncovered at Volition’s and Oncovet’s web page addresses are not included by reference into this document and should not be regarded as element of this doc. Such website addresses are involved in this document as inactive textual references only.
About Oncovet
Oncovet’s mission is to give the greatest possible welcome and cure to the clients you entrust us with. Oncovet strives for excellence and relies on the expertise of its professionals renowned at European stage, as nicely as on the staff supporting them, to present thorough care. Our services consist of medical procedures, cardiology, imaging, radiotherapy, healthcare oncology, and inside drugs. We care for individuals who appear to us from throughout Europe. For more facts, go to: www.oncovet.fr
Volition Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 ()7557 774620
Safe and sound Harbor Assertion
Statements in this press launch could be “forward-hunting statements” within just the that means of Area 27A of the Securities Act of 1933, as amended, and Portion 21E of the Securities Trade Act of 1934, as amended, that concern issues that involve risks and uncertainties that could induce genuine benefits to vary materially from individuals predicted or projected in the forward-looking statements. Words these kinds of as “expects,” “anticipates,” “intends,” “ideas,” “aims,” “targets,” “thinks,” “seeks,” “estimates,” “optimizing,” “opportunity,” “objective,” “implies,” “could,” “would,” “really should,” “may,” “will” and related expressions detect forward-seeking statements. These forward-on the lookout statements relate to, amid other subjects, Volition’s anticipations similar to the probable utilizes, benefits and performance of its Nucleosomics™ engineering system, which include the Nu.Q® Vet Cancer Check, as properly as the expected benefits of its partnership with Oncovet. Volition’s real outcomes could differ materially from those people indicated in these ahead-hunting statements due to several hazards and uncertainties, which includes, devoid of limitation, benefits of scientific studies screening the efficacy of its assessments, a failure by the market to accept Volition’s Nu.Q® Vet Cancer Test or other solutions based mostly on its Nucleosomics™ platform Volition’s failure to secure ample intellectual property protection Volition’s failure to obtain important regulatory clearances or approvals to distribute and market potential products Volition will facial area fierce competitors and its supposed goods may perhaps turn out to be obsolete thanks to the extremely aggressive character of the diagnostics and condition monitoring marketplaces and their speedy technological alter downturns in domestic and foreign economies and other pitfalls, like those people identified in Volition’s most recent Once-a-year Report on Form 10-K and Quarterly Experiences on Form 10-Q, as nicely as other paperwork that Volition data files with the Securities and Exchange Fee. For occasion, if Volition fails to develop and commercialize diagnostic, prognostic or illness checking solutions, it may perhaps be unable to execute its system of functions. Ahead-hunting statements are based on present anticipations, estimates and projections about Volition’s business based, in aspect, on assumptions manufactured by management. These statements are not assures of long run performance and include challenges, uncertainties and assumptions that are hard to forecast. Ahead-searching statements are created as of the day of this release, and, besides as expected by legislation, Volition does not undertake an obligation to update its forward-wanting statements to mirror foreseeable future gatherings or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are logos and/or company marks of VolitionRx Restricted and its subsidiaries. All other logos, assistance marks and trade names referred to in this push launch are the house of their respective homeowners.
In October 2021, Da’Vion Miller was found unconscious in the bathroom of his home in Detroit a week after receiving his first dose of Pfizer’s Covid vaccine.
He had known something was wrong: Then 22, he had started experiencing chest pain two days after getting vaccinated, followed by fatigue, shortness of breath and dizziness.
Miller was rushed to Henry Ford West Bloomfield Hospital, where he was diagnosed with myocarditis, an inflammation of the heart muscle, and pericarditis, an inflammation of the outer lining of the heart. His doctor advised him not to receive a second dose of either the Pfizer or the Moderna vaccines.
“I was like, that’s crazy,” Miller said, noting that he knows the heart inflammation condition following vaccination is extremely rare.
Da’Vion Miller.Courtesy Da’Vion Miller
Miller is one of a very small group of people in the United States who have experienced myocarditis following vaccination with the Pfizer-BioNTech or the Moderna Covid vaccines based on mRNA technology.
Myocarditis is a condition that has long been linked to a number of viral infections, including influenza, coxsackieviruses, as well as Covid. It has also been observed as an infrequent but worrisome side effect of the mRNA Covid vaccines.
Are there long-term risks of myocarditis?
Of the hundreds of millions of Covid vaccine doses given in the U.S. since late 2020, there have been around 1,000 reports of vaccine-related myocarditis or pericarditis in children under age 18, primarily young males, according to the Centers for Disease Control and Prevention.Most of those who developed the condition have fully recovered, although research so far has only looked at how well they’re doing after several months.Some doctors wonder if it can cause permanent damage to the heart.
Now, the first research in the U.S. is underway, tracking adverse health effects — if any — that may appear in the years following a diagnosis of vaccine-associated heart problems. Moderna has already launched two trials, the most recent in September. Pfizer confirmed that at least one of its trials, which will include up to 500 teens and young adults under age 21, is slated to begin in the next couple of months.
The Food and Drug Administration has required that the drugmakers conduct several studies assessing the potential long-term impacts of myocarditis, as part of its approval of the mRNA Covid vaccines in the U.S. Early findings from the research could be published as early as next year, sources told NBC News.
Some of the trials will follow those who developed the condition for as long as five years, according to the FDA’s approval letters. The trials will be monitoring for myocarditis and subclinical myocarditis, which doesn’t cause symptoms.
The FDA declined to comment on Pfizer’s and Moderna’s studies because they are ongoing, but an agency official said the chance of having myocarditis occur following vaccination is “very low.”
The condition does not lead to cardiac-related death, the official said, as claimed by Florida’s surgeon general last month who cited an unpublished analysis of state data.
“There is no evidence of increased risk of deaths following mRNA vaccines compared to individuals who did not get vaccinated,” the official said. “In fact, evidence from well-conducted, peer-reviewed, published studies suggests that the risk of death is higher for unvaccinated individuals for nearly every age group.”
What is known about myocarditis and vaccines?
The vast majority of cases occur in young men, ages 16 to 24, according to the CDC. The agency did not have data available on the total number of cases in young adults 24 and younger, but it estimates there have been 52.4 cases and 56.3 cases per million doses of Pfizer’s and Moderna’s vaccines, respectively.
Symptoms of myocarditis include:
Chest pain
Shortness of breath
Feelings of having a fast-beating, fluttering or pounding heart
A study by Canadian researchers published Monday in the Journal of the American College of Cardiology found that men younger than 40 who got the Moderna vaccine had the highest risk of heart issues, usually within 21 days after the second dose. The study was observational, meaning it doesn’t prove cause and effect but it is one of only a few studies to compare the risk of myocarditis between the Pfizer and the Moderna vaccines.
Last month, Kaiser Permanente scientists found that incidences of myocarditis following a booster dose of either the Pfizer or the Moderna vaccine were higher than after the first dose, but still lower than after the second.
More news on Covid and heart risks
A report from the CDC in April found heart issues were more common after a Covid infection, compared with cardiac issues after vaccination.
After a Covid infection, heart risks remain elevated for up to a year.
Video: CDC says waiting longer between Covid vaccine doses could reduce myocarditis risk.
There has not been a similar reporting pattern observed after receiving the Johnson & Johnson vaccine. Novavax has said no heart inflammation concerns were raised during clinical trials of its vaccine.
Vaccine-associated myocarditis is usually milder than the viral type and most people with the condition make a full recovery, said Dr. Nicola Klein, a vaccine expert at Kaiser Permanente.
In some cases, people who’ve developed myocarditis after a viral infection can suffer scarring along the heart’s tissue, reducing its ability to pump blood and circulate oxygen around the body, said Dr. Leslie Cooper, the chair of the department of cardiology at the Mayo Clinic in Rochester, Minnesota. Cooper joined an expert advisory panel formed by Moderna to monitor its Covid vaccine safety.
It’s unknown how many people with vaccine-associated myocarditis will experience this scarring, he said, noting that about 20{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of people with myocarditis linked to viruses go on to experience heart failure.
“It could be 2{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f}. It could be 0{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f}. It could be 20{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f},” he said, referring to the percentage of people with vaccine-associated myocarditis who could experience long-term heart consequences. “We don’t know the answer.”
The CDC recently published a study in The Lancet that looked at health outcomes in more than 500 teens and young adults at least 90 days after the onset of myocarditis following an mRNA vaccination.
Most got better at least three months after symptoms. Other findings from the CDC report included:
About a quarter of the patients in the study were prescribed daily medication related to myocarditis at their last health care provider follow-up.
A little more than 100 of the patients had not been cleared for physical activity.
In addition, 81 patients had an abnormality on their cardiac MRI — although that doesn’t necessarily mean that they are at risk for any adverse health problems.
The CDC will follow the patients who had not fully recovered for 12 months, said Ian Kracalik, the study’s lead author and CDC epidemiologist.
Are some patients at higher risk for heart issues, such as arrhythmias? Dr. Dongngan Truong, a pediatrician at the University of Utah Health, said Pfizer researchers will be trying to determine the factors.
Pfizer, in collaboration with the Pediatric Heart Network, will be monitoring participants for five years, according to Truong, a co-lead on the Pfizer study. The Pfizer study will include people who were previously hospitalized with vaccine-associated myocarditis, and it will also follow those who were more recently diagnosed.
The team will also compare the patients to a subset of patients with multisystem inflammatory syndrome in children, also known as MIS-C, which is associated with a Covid infection.
Truong said that monitoring what happens to younger people and children after Covid infections is “especially important” to get a clearer understanding of the risks of the illness, compared to any possible side effects of the vaccines.
The Pfizer study, which will take place in the U.S. and Canada, has not begun enrollment yet, although the research team has already identified more than 250 patients with myocarditis, she said.
The first findings could be released sometime next year, Truong said.
Scientists still don’t have a clear explanation yet for why the vaccines cause the condition,according to Dr. Paul Burton, Moderna’s chief medical officer. He expects the virus’s spike protein, once produced in the cell after vaccination, may generate a reaction in the body that can cause inflammation in the heart.
“We don’t understand yet and there’s no good mechanism to explain it,” he said.
The two myocarditis studies Moderna has started, one of which is in collaboration with the American College of Cardiology, are using public and private data of tens of millions of people who received the company’s vaccine and how they fared, Burton said.
“Did they get myocarditis? When did it occur? How was it treated? How severe was it?” he said.
Moderna is also conducting two additional studies with the European Medicines Agency that will span five different countries. The drugmaker will assess outcomes for a year or more, Burton said, with data expected to be made public around next summer.
He said he doesn’t expect “big surprises.”
In recent weeks, multiple new versions of the omicron variant, including BQ.1 and BQ.1.1, have begun circulating widely in the U.S., increasing the risk of reinfections, particularly for those who haven’t yet received a booster dose.
“The emerging new variants that we see on the landscape are very, very infectious, and really have a high risk,” Burton said. “The benefit ratio of getting vaccinated outweighs the risks of getting vaccinated. And that is absolutely true for myocarditis.”
Klein, of Kaiser Permanente, agreed, saying the overall risk of vaccine-associated myocarditis is “very low.”
A year later, Miller is still experiencing symptoms, including chest pain. While there is comfort in knowing his situation is rare, he said, he’s been in and out of the hospital since his diagnosis, which he said has been difficult for him.
